Late-Occurring Stroke Among Long-Term Survivors of Childhood Leukemia and Brain Tumors: A Report From the Childhood Cancer Survivor Study

Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Journal of Clinical Oncology (Impact Factor: 18.43). 12/2006; 24(33):5277-82. DOI: 10.1200/JCO.2006.07.2884
Source: PubMed


This report examines the incidence of and risk factors for strokes that occur in > or = 5-year survivors of childhood leukemia and brain tumors.
The rate of first occurrence of self-reported late-occurring strokes was determined for leukemia survivors (n = 4,828), brain tumor survivors (n = 1,871), and a comparison group of a random sample of cancer survivor siblings (n = 3,846). Relative risks (RRs) and 95% confidence intervals (CIs) of stroke by treatment exposures were examined by multivariate analyses.
Thirty-seven leukemia survivors and 63 brain tumor survivors reported a late-occurring stroke. The rate of late-occurring stroke for leukemia survivors was 57.9 per 100,000 person-years (95% CI, 41.2 to 78.7). The RR of stroke for leukemia survivors compared with the sibling comparison group was 6.4 (95% CI, 3.0 to 13.8; P < .0001). The rate of late-occurring stroke for brain tumor survivors was 267.6 per 100,000 person-years (95% CI, 206.8 to 339.2). The RR of stroke for brain tumor survivors compared with the sibling comparison group was 29.0 (95% CI, 13.8 to 60.6; P < .0001). Mean cranial radiation therapy (CRT) dose of > or = 30 Gy was associated with an increased risk in both leukemia and brain tumor survivors in a dose-dependent fashion, with the highest risk after doses of > or = 50 Gy CRT.
Survivors of childhood leukemia and brain tumors, particularly those with brain tumors treated with CRT at doses of greater than 30 Gy, are at an increased risk of stroke.

Download full-text


Available from: James G Gurney, Nov 09, 2015
  • Source
    • "As in HL, radiation therapy is believed to play an important role in the development of long-term toxicities. Some of the long-term toxicities recognized to date include moderate to severe neurological or cognitive impairment in 3–15% of patients, a sixfold increase in risk of stroke, a threefold increase in risk of short stature, infertility (in post-pubescent males) and secondary malignancies including brain tumors and secondary leukemia (Ise et al., 1986; Neglia et al., 1991; Relling et al., 1999; von der Weid and Swiss Pediatric Oncology Group, 2001; Bowers et al., 2006; Chow et al., 2007 ). In addition cytotoxic chemotherapy treatment is a recognized cause of “secondary” leukemias, with the risk reaching 5% for most ALL survivors and a 20% risk in survivors of T cell ALL at 6 years (Pui et al., 1989). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the last half of the century, advances in the systemic therapy of cancer, including chemotherapy, hormonal therapy, targeted therapy, and immunotherapy have been responsible for improvements in cancer related mortality in developed countries even as the population continues to age. Although such advancements have yet to benefit all cancer types, systemic therapies have led to an improvement in overall survival in both the adjuvant and metastatic setting for many cancers. With the pressure to make therapies available as soon as possible, the side-effects of systemic therapies, in particular long-term side-effects are not very well characterized and understood. Increasingly, a number of cancer types are requiring long-term and even lifelong systemic therapy. This is true for both younger and older patients with cancer and has important implications for each subset. Younger patients have an overall greater expected life-span, and as a result may suffer a greater variety of treatment related complications in the long-term, whereas older patients may develop earlier side-effects as a result of their frailty. Because the incidence of cancer in the world will increase over the next several decades and there will be more people living with cancer, it is important to have an understanding of the potential side-effects of new systemic therapies. As an introductory article, in this review series, we begin by describing some of the major advances made in systemic cancer therapy along with some of their known side-effects and we also make an attempt to describe the future of systemic cancer therapy.
    Full-text · Article · May 2013 · Frontiers in Pharmacology
  • Source
    • "It is well documented that radiotherapy can induce a type of vascular disease, termed vasculopathy.2)3) In addition, it has become increasingly evident that cranial radiation therapy increases the risk of stroke for cancer survivors.4)5) Although radiation-induced occlusive vasculopathies are well documented, little is known about the characteristics of radiation-induced intracranial aneurysms and their optimal treatment strategy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We report herein a case of a radiation-induced aneurysm. A 69-year-old woman presented with subarachnoid hemorrhage. Eight years previously, she had undergone cranial radiation therapy (total dose of 59.4 Gy) as adjuvant therapy after surgical resection for a chondrosarcoma that was destroying her sphenoid sinus. The patient underwent catheter angiography, which revealed an aneurysm of the anterior communicating artery and luminal narrowing and irregularity in the petrous and lacerum segments of the right internal carotid artery. We attempted surgical clipping of the aneurysm, but there was repeated bleeding. Finally the aneurysm was treated with endovascular trapping. Potentially fatal bleeding also occurred from her internal carotid artery, which had also been irradiated during the previous cranial radiation therapy. We stopped the bleeding with endovascular coil embolization. Because of diffuse vascular changes of the cerebral vessels within irradiated fields, special attention must be paid to their treatment.
    Full-text · Article · Dec 2012
  • Source
    • "Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy and adult survivors of childhood-onset ALL account for about 28% of the Childhood Cancer Survival Study cohort [1]. Among survivors of childhood leukemia (ALL in about 90%), the relative hazard of congestive heart failure, myocardial infarction and late-occurring stroke was increased 4.2-fold, 3.3-fold and 6.4-fold, respectively, with the reference to the sibling control groups [3] [4]. Additionally, in ALL survivors standardized CV mortality ratio was elevated 4.2-fold compared with the age-, sex-and year-matched US population [1]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adult survivors of childhood malignancy are predisposed to late cardiovascular (CV) complications. Our aim was to estimate plasma levels of the endogenous nitric oxide formation inhibitor asymmetric dimethylarginine (ADMA), in long-term survivors of childhood acute lymphoblastic leukemia (ALL) treated with only chemotherapy. ADMA and its isomer symmetric dimethylarginine (SDMA) were measured in 25 former ALL patients (aged 18-28 years) who had survived without recurrent disease ≥ 5 years from completing chemotherapy without cranial irradiation, and in 20 healthy controls (aged 20-31 years). Characteristics of the both groups were similar, except for lower high-density lipoproteins-cholesterol (HDL-C) in ALL survivors. Compared to controls, the former ALL patients exhibited significant, albeit small, rises in levels of ADMA (0.63 ± 0.09 [SD] vs. 0.57 ± 0.07 μmol/L; p=0.016), but not SDMA, with a consequently increased ADMA to SDMA ratio (1.08 ± 0.22 vs. 0.91 ± 0.16; p=0.004). The effect of former ALL on ADMA was attenuated (intergroup p=0.10 [ANCOVA]) upon adjustment for HDL-C (ADMA vs. HDL-C regression coefficient: -0.065 ± 0.030 [SEM]; p=0.03). ADMA is elevated in adult childhood ALL survivors, which can reflect late detrimental chemotherapy effects, partially related to minor lipid profile changes. Whether these subtle ADMA elevations might herald future CV morbidity, remains to be elucidated.
    Full-text · Article · Jul 2012 · Disease markers
Show more